Efficacy of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study
Authors:
Open Access
- 27 March 2012
- journal article
- research article
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 38 (2) , 94-101
Abstract
Objectives: The aim of this Phase III, multicentre, open-label, randomised study was to compare the efficacy and safety of ethinylestradiol (EE)/drospirenone (DRSP) in a new flexible extended regimen that allowed the management of intracyclic (breakthrough) bleeding (MIB) with that of EE/DRSP in a conventional 28-day regimen in women with moderate-to-severe primary dysmenorrhoea.Methods: Women (aged 18–40 years) with moderate-to-severe primary dysmenorrhoea-related pain received a flexible extended regimen with MIB (flexibleMIB; minimum 24, maximum 120 days of continuous tablet intake for a flexible number of cycles to reach a treatment duration of at least 140 days with 4-day breaks between cycles) or a conventional 28-day regimen (24 active and four placebo tablets for five cycles) of EE/DRSP. The primary outcome was the number of days with dysmenorrhoeic pain over 140 days. Secondary outcomes included other dysmenorrhoea-related pain outcomes, bleeding profile, satisfaction and safety.Results: Overall, 223 patients received study medication. There were significantly fewer days with dysmenorrhoeic pain with the flexibleMIBregimen than the conventional regimen (difference −4.2 days, 95% CI −6.5 to −2.0;p=0.0003), as well as considerably fewer days with at least moderate dysmenorrhoeic pain (difference −2.5 days, 95% CI −3.7 to −1.3), dysmenorrhoeic pain that interfered with daily activities (difference −2.2 days, 95% CI −4.2 to −0.1) and pelvic pain (difference −3.4 days, 95% CI −5.9 to −0.9). Adverse events were similar with both regimens.Conclusions: Compared with the conventional regimen, the flexible extended regimen of EE/DRSP with MIB was associated with a significantly greater reduction in days with dysmenorrhoeic pain in women with moderate-to-severe primary dysmenorrhoea. The flexibleMIBregimen was also associated with greater improvements in dysmenorrhea according to the Clinical Global Impression rating scale and was generally well tolerated.Keywords
This publication has 15 references indexed in Scilit:
- Extended Cycles with the Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mgClinical Drug Investigation, 2011
- A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.2010
- Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized studyContraception, 2010
- Oral contraceptive pill for primary dysmenorrhoeaCochrane Database of Systematic Reviews, 2009
- Primary DysmenorrheaObstetrics & Gynecology, 2006
- Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception2005
- Dysmenorrhea.2005
- Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trialContraception, 2003
- Primary dysmenorrhea.1999
- An epidemiologic study of young women with dysmenorrheaAmerican Journal of Obstetrics and Gynecology, 1982